Haleon plc (HLN) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Weybridge, United Kingdom. The current CEO is Brian James McNamara.
HLN has IPO date of 2022-07-25, 24,561 full-time employees, listed on the NYSE, a market capitalization of $43.23B.
Haleon plc is a consumer healthcare company headquartered in Brentford, United Kingdom, engaged in the research, development, manufacture, and distribution of over-the-counter health and wellness products across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. The company's extensive portfolio spans therapeutic oral health, pain relief, respiratory health, digestive health, vitamins, minerals, and supplements, featuring globally recognized brands including Panadol, Voltaren, Advil, Sensodyne, Theraflu, Otrivin, Polident, parodontax, and Centrum. Since its incorporation in 2021 and rebranding to Haleon plc in February 2022, the company has positioned itself as a leading player in the consumer healthcare sector.
